Avalo Therapeutics, Inc. ($AVTX)
Filing Information
| Accession Number | 0001810417-26-000019 |
|---|---|
| Form Type | 4 |
| Filing Date | Aug 19, 2026 |
| Document | View SEC Filing |
Transactions
9
Total Shares
216,429
Total Value
$2,160,317.01
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer | Common Stock | โ | Aug 17, 2026 | Exercise/Conversion | 37,945 | $9.88 | $374,896.60 | 78,718 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 17, 2026 | Exercise/Conversion | 2,876 | $9.88 | $28,414.88 | 81,594 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 17, 2026 | Sale | 37,945 | $19.85 | $753,333.47 | 43,649 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 17, 2026 | Sale | 3,749 | $19.94 | $74,762.18 | 39,900 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 18, 2026 | Exercise/Conversion | 31,031 | $9.88 | $306,586.28 | 70,931 | Direct | โ | View Details | |
Chief Financial Officer | Common Stock | โ | Aug 18, 2026 | Sale | 31,031 | $20.05 | $622,323.60 | 39,900 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Aug 17, 2026 | Exercise/Conversion | 37,945 | $0.00 | $0.00 | 130,149 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Aug 17, 2026 | Exercise/Conversion | 2,876 | $0.00 | $0.00 | 127,273 | Direct | โ | View Details | |
Chief Financial Officer | Stock Option (Right to Buy) | Derivative | Aug 18, 2026 | Exercise/Conversion | 31,031 | $0.00 | $0.00 | 96,242 | Direct | โ | View Details |